Regulatory News:
ADOCIA (Paris:ADOC) (Euronext Paris: FR0011184241 ADOC the "Company") confirms its eligibility for the "PEA PME" stock savings tax regime, which decree has been published in the French Journal Officiel on March 4, 2014 (Decree n 2014-283), and which entered into force on March 6, 2014.
To be eligible for the "PEA PME", the shares must have been issued by a company whose market capitalization is below one billion euros, of which no legal person holds more than 25% of its capital, which has less than 5,000 employees, and an annual turnover not exceeding 1.5 billion euros or a total balance sheet less than 2 billion euros.
Adocia meets all of these conditions.
About ADOCIA
Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins and peptides. Adocia's portfolio of injectable treatments for diabetes, featuring five clinical-stage products and three preclinical products, is among the largest and most differentiated of the industry. Adocia expanded its portfolio to develop treatments for obesity and short bowel syndrome.
The proprietary BioChaperone technological platform is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. Adocia customizes BioChaperone to each protein for a given application to address specific patient needs.
Adocia's clinical pipeline includes four novel insulin formulations for the treatment of diabetes: two ultra-rapid formulations of insulin analog lispro (BioChaperone Lispro U100 and U200), a rapid-acting formulation of human insulin (HinsBet U100) and a combination of basal insulin glargine and rapid-acting insulin lispro (BioChaperone Combo). An aqueous formulation of human glucagon (BioChaperone Human Glucagon) successfully completed a Phase 1 trial. Adocia also develops a prandial combination of human insulin with amylin analog pramlintide (BioChaperone Pramlintide hIns), two combinations of insulin glargine with GLP-1 receptor agonists (BioChaperone Glargine Dulaglutide and BioChaperone Glargine Liraglutide), a ready-to-use aqueous formulation of teduglutide (BioChaperone Teduglutide) and a ready-to-use combination of glucagon and exenatide (BioChaperone Glucagon Exenatide), all of which are in preclinical development.
Adocia aims to deliver "Innovative medicine for everyone, everywhere."
To learn more about Adocia, please visit us at www.adocia.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20180316005487/en/
Contacts:
Adocia
Gérard Soula
Chairman and CEO
contactinvestisseurs@adocia.com
Ph. +33 4 72 610 610
or
Adocia Press Relations Europe
MC Services AG
Raimund Gabriel
adocia@mc-services.eu
Ph. +49 89 210 228 0
or
Adocia Investor Relations USA
The Ruth Group
Tram Bui
tbui@theruthgroup.com
Ph.: +1 646 536 7035